Improved Method of Recombinant AAV2 Delivery for Systemic Targeted Gene Therapy
Open Access
- 1 July 2002
- journal article
- Published by Elsevier BV in Molecular Therapy
- Vol. 6 (1), 106-112
- https://doi.org/10.1006/mthe.2001.0636
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- Infection of Purified Nuclei by Adeno-associated Virus 2Molecular Therapy, 2001
- Inhibition of recombinant adeno-associated virus (rAAV) transduction by bronchial secretions from cystic fibrosis patientsGene Therapy, 2000
- Infectious Entry Pathway of Adeno-Associated Virus and Adeno-Associated Virus VectorsJournal of Virology, 2000
- Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vectorNature Genetics, 2000
- Impaired Intracellular Trafficking of Adeno-Associated Virus Type 2 Vectors Limits Efficient Transduction of Murine FibroblastsJournal of Virology, 2000
- Recombinant adeno-associated virus purification using novel methods improves infectious titer and yieldGene Therapy, 1999
- Adeno-associated virus 2 co-receptors?-first replyNature Medicine, 1999
- αVβ5 integrin: a co-receptor for adeno-associated virus type 2 infectionNature Medicine, 1999
- Sustained secretion of human alpha-1-antitrypsin from murine muscle transduced with adeno-associated virus vectorsProceedings of the National Academy of Sciences of the United States of America, 1998
- Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic proteinProceedings of the National Academy of Sciences, 1996